King Luther Capital Management Corp Has $274.95 Million Stake in Danaher Corporation $DHR

King Luther Capital Management Corp lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 11.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,386,811 shares of the conglomerate’s stock after selling 172,655 shares during the period. Danaher accounts for about 1.1% of King Luther Capital Management Corp’s portfolio, making the stock its 19th largest position. King Luther Capital Management Corp’s holdings in Danaher were worth $274,949,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. WFA of San Diego LLC bought a new stake in Danaher during the 2nd quarter valued at $26,000. Howard Hughes Medical Institute bought a new stake in shares of Danaher during the second quarter worth about $27,000. TruNorth Capital Management LLC acquired a new stake in shares of Danaher in the 3rd quarter worth about $28,000. Tripletail Wealth Management LLC bought a new position in Danaher in the 3rd quarter valued at about $31,000. Finally, Heartwood Wealth Advisors LLC bought a new position in shares of Danaher in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on DHR shares. Robert W. Baird set a $251.00 price target on shares of Danaher in a report on Thursday, January 29th. Evercore reissued an “outperform” rating and issued a $254.00 price objective on shares of Danaher in a report on Wednesday, January 28th. Morgan Stanley started coverage on shares of Danaher in a research note on Monday, December 1st. They issued an “overweight” rating and a $270.00 price objective for the company. Argus set a $265.00 price target on Danaher in a research report on Wednesday, January 14th. Finally, Leerink Partners upped their price target on Danaher from $260.00 to $270.00 and gave the company an “outperform” rating in a research report on Friday, January 16th. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.86.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher agreed to buy Masimo for roughly $9.9 billion (cash, $180 per share), adding pulse oximetry and patient-monitoring tech to its Diagnostics segment — management says Masimo will operate as a stand‑alone business, preserving its commercial footprint. Danaher to buy Masimo for $9.9 billion
• Positive Sentiment: Deal size and strategic rationale frame this as one of 2026’s largest med‑tech buyouts — investors view it as a clear move to bulk up Diagnostics and widen cross‑sell and lifecycle offerings. Danaher’s $9.9B Masimo Deal Marks One of 2026’s Largest Medtech Buyouts
• Positive Sentiment: Market reaction: Masimo shares surged on the announcement, and Danaher shares moved on acquisition buzz as traders priced in strategic upside and potential revenue/scale benefits. Shares of Masimo, Danaher Moving on Acquisition Buzz
• Neutral Sentiment: Coverage notes Danaher’s solid underlying financials and relatively conservative growth projections — this suggests the deal is being integrated into a cautious growth outlook rather than signaling aggressive upside guidance. Danaher’s Masimo acquisition: Solid financials, conservative growth projections
• Neutral Sentiment: Danaher’s broader business shows stabilizing areas (notably bioprocessing), which provides a steadier earnings base to absorb bolt‑on M&A. Danaher Corp. (DHR) Signaled Signs of a Stable Bioprocessing Segment
• Negative Sentiment: The $9.9B all‑cash price and premium paid could pressure near‑term free cash flow and capital allocation; investors will watch integration costs, any leverage changes, and whether the deal proves accretive. Danaher Strikes $10 Billion Deal for Masimo

Danaher Price Performance

Shares of Danaher stock opened at $208.51 on Thursday. The firm has a market capitalization of $147.28 billion, a PE ratio of 41.37, a price-to-earnings-growth ratio of 2.79 and a beta of 0.91. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $242.80. The business’s 50-day moving average price is $227.62 and its 200-day moving average price is $215.72.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, beating the consensus estimate of $2.14 by $0.09. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The company had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.79 billion. During the same quarter last year, the firm earned $2.14 EPS. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. Sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were given a $0.32 dividend. The ex-dividend date was Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is presently 25.40%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.